The International Myeloma Foundation is committed to action on issues that affect patients and their families. Through our advocacy efforts, we ensure that the patient perspective is heard when legislators consider important and impactful changes to our national health care system. Our advocacy team regularly meets with congressional staffers on wide ranging issues from those that impact patient access to drugs, such as oral parity legislation, to fighting for increases in research funding through agencies like the National Institutes of Health.
Equally important are the efforts of our patient advocates. The advocacy team trains and guides patients and family through the pitfalls of patient activism at the federal level and provides opportunities for every patient to take action from their own home. With your help, the IMF supports legislation that betters the lives of multiple myeloma patients nationwide.
This bipartisan piece of legislation would create a presumption of service connection for diseases associated with firefighting, which includes myeloma. By creating this presumption of service connection for military firefighters.
116th Congress H.R. 663 and S. 191 burn pit accountability act
The Cancer Drug Parity Act (H.R. 1730 in the House and S. 741 in the Senate) ensures fairness in cost-sharing for all anticancer regimens. Health insurance cost-sharing schemes should not create barriers to cancer patients' ability to access potentially life-saving medicines.
On January 17, 2019, The IMF joined with over 50 patient advocacy groups in an ad campaign to ensure Medicare Part D patients continue to have access to drugs in the Six Protected Classes, which include many drugs used to treat cancer.
H.R. 913 aims to improve access to clinical trials for Medicaid enrollees by requiring states to provide coverage of routine patient costs in connection with participation in qualifying clinical trials.
Our Advocacy Team conveys to the Administration the perspectives and experiences of myeloma patients affected by high out-of-pocket drug costs.